@article {1653583,
	title = {The Treatment of Myelin Oligodendrocyte Glycoprotein Antibody Disease: A State-of-the-Art Review},
	journal = {J Neuroophthalmol},
	volume = {42},
	number = {3},
	year = {2022},
	month = {2022 Sep 01},
	pages = {292-296},
	abstract = {BACKGROUND: Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is an important etiology of neurologic morbidity and specifically, atypical, and relapsing optic neuritis. This review summarizes acute treatment and long-term prevention approaches in MOGAD. EVIDENCE ACQUISITION: PubMed and Google Scholar databases were manually searched and reviewed. RESULTS: We review the evidence base for acute treatment of MOGAD with corticosteroids and adjunct therapies, such as intravenous immunoglobulin (IVIg) and plasma exchange. We discuss the utility of prolonged corticosteroid tapering after the acute attack. We then summarize the commonly used disease-modifying treatments for relapsing MOGAD, including chronic low-dose corticosteroids, classic antirheumatic immune suppressants, biologic agents, and IVIg. CONCLUSIONS: While acute MOGAD attacks are usually treated with high-dose IV corticosteroids, longer oral corticosteroid tapers may prevent rapid relapse. Multiple long-term treatment strategies are being employed in recurrent MOGAD, with IVIg is emerging as probably the most effective therapy.},
	keywords = {Adrenal Cortex Hormones, Aquaporin 4, Autoantibodies, Humans, Immunoglobulins, Intravenous, Myelin-Oligodendrocyte Glycoprotein, Neuromyelitis Optica, Optic Neuritis},
	issn = {1536-5166},
	doi = {10.1097/WNO.0000000000001684},
	author = {Chwalisz, Bart K and Michael Levy}
}
